Logo

American Heart Association

  16
  0


Final ID: MP2606

BMP9 drives vasoactive gene expression in endothelial cells via non-canonical ALK1-SMAD3 signaling

Abstract Body (Do not enter title and authors here): Rationale: The role of BMP9 in pulmonary arterial hypertension (PAH) remains controversial. Loss-of-function GDF2/BMP9 mutations in heritable PAH suggest its function as a vascular endothelial homeostasis factor, however, modulating BMP9 signaling in experimental pulmonary hypertension (PH) models can yield pathogenic or protective effects. The impact of BMP9 upon intracellular and intercellular angiogenic signaling cascades remains poorly understood.
Methods/Results: We analyzed BMP9-mediated transcription in pulmonary microvascular endothelial cells (PMVEC) derived from controls and patients, and in the presence or absence of co-cultured pulmonary artery smooth muscle cells (PASMC). We tested recombinant BMP9, BMP9/BMP10 ligand trap ALK1-Fc, anti-BMP9, and activin/GDF ligand trap ACTRIIA-Fc in hypoxia, SUGEN5416+hypoxia (SU-Hx) and monocrotaline (MCT) experimental PH rodent models. The BMP9-regulated secretome of ECs was examined for potential modulation of PASMC phenotype and function. Inhibition of BMP9 and/or BMP10 was protective whether administered before or after the development of experimental PH, and attenuated experimental PH when administered therapeutically in the SU-Hx model. In PMVEC, BMP9 elicited expression of vasoactive genes that were also elevated in experimental PH and human PAH lungs, including EDN1, CXCL12, IGFBP4, COL18A1, VEGFA, PDGFB, and SERPINE1, several of which were normalized in lungs of SU-Hx rats with anti-BMP9 treatment. Several of these genes required non-canonical activation of SMAD3 downstream of BMPR2, ALK1, and ENG. Promoter analysis of human ET-1 revealed cooperation of SMAD3 and SMAD1/5 binding elements is required for BMP9-mediated expression of ET-1. Co-culture models revealed the essential role of BMP9-mediated PMVEC paracrine signaling in modulating PASMC contractile phenotype markers (CNN1; TAGLN), which was attenuated by anti-CXCL12, CXCR4 antagonist, or anti-BMP9.
Conclusions: BMP9 is a central regulator of vasoactive endothelial genes via ALK1-SMAD3 signaling that modulate PASMC phenotype and contribute to experimental PH.
  • Sangam, Shreya  ( Massachusetts General Hospital , Boston , Massachusetts , United States )
  • Nathans, Robin  ( Pfizer , Cambridge , Massachusetts , United States )
  • Zeghibe, Ana  ( Massachusetts General Hospital , Boston , Massachusetts , United States )
  • Worst, Lily  ( Massachusetts General Hospital , Boston , Massachusetts , United States )
  • Mcneil, Megan  ( Massachusetts General Hospital , Boston , Massachusetts , United States )
  • Kim, Stephanie  ( Massachusetts General Hospital , Boston , Massachusetts , United States )
  • Bocobo, Geoffrey A  ( Massachusetts General Hospital , Boston , Massachusetts , United States )
  • Shin, Elizabeth  ( Massachusetts General Hospital , Boston , Massachusetts , United States )
  • Nikolic, Ivana  ( Massachusetts General Hospital , Boston , Massachusetts , United States )
  • Szulcek, Robert  ( Charite University , Berlin , Germany )
  • Bogaard, Harm  ( VU UNIV MEDICAL CENTER , Amsterdam , Netherlands )
  • Zhong, Ying  ( Massachusetts General Hospital , Boston , Massachusetts , United States )
  • Lavoie, Sydney  ( Pfizer , Cambridge , Massachusetts , United States )
  • Martinez-hackert, Erik  ( Michigan State University , Detroit , Michigan , United States )
  • Berasi, Stephen  ( Pfizer , Cambridge , Massachusetts , United States )
  • Huard, Christine  ( Pfizer , Cambridge , Massachusetts , United States )
  • Gipson, Gregory  ( Massachusetts General Hospital , Boston , Massachusetts , United States )
  • Hart, Kevin  ( Pfizer , Cambridge , Massachusetts , United States )
  • Fast, Eva  ( Pfizer , Cambridge , Massachusetts , United States )
  • Pascual, Fernando Rodriguez  ( Centro de Biología Molecular Severo Ochoa Consejo Superior de Investigaciones , Madrid , Spain )
  • Yu, Paul  ( Massachusetts General Hospital , Boston , Massachusetts , United States )
  • Yang, Peiran  ( Peking Union Medical College , Beijing , China )
  • Bagarova, Jana  ( Massachusetts General Hospital , Boston , Massachusetts , United States )
  • Troncone, Luca  ( Massachusetts General Hospital , Boston , Massachusetts , United States )
  • Tumelty, Kathleen  ( Pfizer , Cambridge , Massachusetts , United States )
  • Kovalenko, Oleg  ( Pfizer , Cambridge , Massachusetts , United States )
  • Rajesh, Shreyas  ( Massachusetts General Hospital , Boston , Massachusetts , United States )
  • Convington, Taylor  ( Massachusetts General Hospital , Boston , Massachusetts , United States )
  • Author Disclosures:
    Shreya Sangam: DO NOT have relevant financial relationships | Robin Nathans: No Answer | Ana Zeghibe: No Answer | Lily Worst: No Answer | Megan McNeil: DO NOT have relevant financial relationships | Stephanie Kim: No Answer | Geoffrey A Bocobo: DO NOT have relevant financial relationships | Elizabeth Shin: No Answer | ivana nikolic: DO NOT have relevant financial relationships | Robert Szulcek: DO NOT have relevant financial relationships | Harm Bogaard: DO have relevant financial relationships ; Employee:LinXis Biopharmaceuticals:Active (exists now) ; Consultant:Vivus:Past (completed) ; Consultant:Liquidia:Past (completed) ; Research Funding (PI or named investigator):Ferrer:Active (exists now) ; Research Funding (PI or named investigator):MSD:Active (exists now) ; Speaker:MSD:Active (exists now) ; Consultant:Merck:Active (exists now) | Ying Zhong: No Answer | Sydney Lavoie: No Answer | Erik Martinez-Hackert: No Answer | Stephen Berasi: No Answer | Christine Huard: DO NOT have relevant financial relationships | Gregory Gipson: No Answer | Kevin Hart: DO have relevant financial relationships ; Employee:Pfizer Inc.:Active (exists now) | Eva Fast: No Answer | Fernando Rodriguez-Pascual: DO NOT have relevant financial relationships | Paul Yu: DO have relevant financial relationships ; Ownership Interest:Keros Therapeutics:Active (exists now) ; Research Funding (PI or named investigator):Gossamer Bio:Active (exists now) ; Consultant:OrphAi:Active (exists now) ; Research Funding (PI or named investigator):AllRock:Active (exists now) ; Research Funding (PI or named investigator):Ingenia Therapeutics:Active (exists now) ; Research Funding (PI or named investigator):Pfizer:Active (exists now) | Peiran Yang: No Answer | Jana Bagarova: DO NOT have relevant financial relationships | Luca Troncone: No Answer | Kathleen Tumelty: No Answer | Oleg Kovalenko: No Answer | Shreyas Rajesh: DO NOT have relevant financial relationships | Taylor Convington: No Answer
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

The Endothelium Unveiled: Orchestrator of Vascular Remodeling in PH

Monday, 11/10/2025 , 10:45AM - 11:45AM

Moderated Digital Poster Session

More abstracts from these authors:
Biased small molecule RXFP1 agonists ameliorate experimental pulmonary hypertension and RV hypertrophy

Rajesh Shreyas, Agoulnik Alexander, Rajagopal Sudarshan, Yu Paul, Sangam Shreya, Triantafyllou Georgios, Pham Uyen, Troncone Luca, Gipson Gregory, Henderson Mark, Marugan Juan, Agoulnik Irina

Biased Activation of RXFP1 signaling via ML290 Attenuates Experimental Pulmonary Hypertension

Sangam Shreya, Brackin Riley, Zeghibe Ana, Shin Elizabeth, Agoulnik Irina, Marugan Juan, Agoulnik Alexander, Rajagopal Sudarshan, Yu Paul, Triantafyllou Georgios, Pham Uyen, Troncone Luca, Yung Lai-ming, Chundi Anand, Darbha Srikrishna, Gipson Gregory, Rajesh Shreyas

You have to be authorized to contact abstract author. Please, Login
Not Available